Trials / Completed
CompletedNCT00881855
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fed Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefprozil 500 mg Tablets (Sandoz, GmbH) | |
| DRUG | Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA) |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2009-04-15
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00881855. Inclusion in this directory is not an endorsement.